MILWAUKEE, Oct. 3, 2023 /PRNewswire/ -- Ademi LLP is investigating POINT (Nasdaq:PNT) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly.
Read more at prnewswire.comShareholder Alert: Ademi LLP investigates whether POINT Biopharma Global, Inc. has obtained a Fair Price in its transaction with Eli Lilly
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here